Clinical trials: Human Papilloma Virus Infection
Cervix Cancer, HIV Infections
Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV
This Clinical Trials Network for Human Immunodeficiency Virus (HIV)-Associated Cervical Cancer Screening and Treatment Optimization (CASCADE) C3001-A trial aims to assess how the introduction of a…
- Conditions
- Cervix Cancer, HIV Infections, HPV Infection
- Trial name
- CASCADE3001A (NCT07428330)
- Testing
- Model 1- Screening in Clinic Only, Model 2 - Screening in Clinic and Community
- Where
- Uganda
- Volunteers
- 7,597 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Infections, Papillomavirus
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years
The purpose of this study is to evaluate the immunogenicity and safety of two doses of GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine when co-administered with GSK Biologicals' HAV vaccine according to 0, 6 month schedule…
- Trial name
- NCT02082639
- Testing
- Cervarix™, Havrix
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Infection
Probiotc Lactobacillus Crispatus-M247 (Crispact®) Supplementation in the Sterilization of High-risk Human Papilloma (HPV-HR) Viruses
There is growing scientific interest in probiotic supplementation as a possible therapy for clearing the human papillomavirus (HPV) infection and reducing the risk of developement of cervical cancer.
- Trial name
- NCT06245486
- Testing
- Crispact®
- Volunteers
- 150 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Condyloma
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
This is a double-blind placebo controlled, randomized, phase 2 study to assess the safety, tolerability, pharmacokinetics and efficacy of twice daily topical applications of AP611074 5% Gel for up to 16 weeks in condyloma patients
- Trial name
- NCT02724254
- Testing
- AP611074 5% gel
- Where
- 12 sites in Argentina, Chile and 2 more
- Volunteers
- 218 people
- Sponsor
- Vaxart
Human Papilloma Virus
Patient Self-sampling of HPV to Screen for Cervical Cancer
The purpose of this study is to validate a patient self-sampling vaginal collection kit and laboratory testing for the detection of HPV (human papillomavirus) infection.
- Trial name
- NCT05600283
- Testing
- Swab kit (COBAS HPV 4800 Assay -Evalyn brush), Clinician-collection of cervical sample for HPV testing
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Mayo Clinic
Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm
ESCUDDO Long Term Follow Up
This phase IV trial evaluates the long term protection provided by either one or two doses of the 9v human papillomavirus (HPV) vaccine for participants who were part of the ESCUDDO study.
- Trial name
- ESCUDDO LTFU (NCT07706673)
- Testing
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Recombinant Human Papillomavirus Nonavalent Vaccine
- Where
- Costa Rica
- Volunteers
- 13,700 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Human Papilloma Virus, Cervical Intraepithelial Neoplasia
HPV-based Screening Among Women 23-29 Years of Age
The aim of the trial is to determine whether organized screening with primary HPV analysis provide higher cancer protection in the age group 23-29 years compared to primary cytology.
- Conditions
- Human Papilloma Virus, Cervical Intraepithelial Neoplasia, Cervical Cancer
- Trial name
- NCT05229679
- Testing
- HPV testing
- Where
- 2 sites in Sweden
- Volunteers
- 180,000 people
- Sponsor
- Karolinska Institutet
Human Papilloma Virus Infection
Understanding Women's Values in Managing Human Papillomavirus (HPV)
Almost all cervical cancers are caused by infection with a high-risk (hr) HPV. In March 2020, the Scottish Cervical Screening programme changed from a test to look for abnormal cervical cells caused by hr-HPV to a test that looks…
- Trial name
- NCT06123533
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Aberdeen
ASC-US, Human Papilloma Virus
Can B12 and Folate Levels Predict HPV Penetration in Patients With ASCUS?
Non-classified atypical squamous cells (ASCUS) is the most common abnormal cervical cytology (%39). The risk of cervical intraepithelial neoplasia 2-3 is 5% and the risk of carcinoma is around 0.1% after diagnosis.
- Trial name
- NCT03903952
- Testing
- Vitamin B12 and folate
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sanliurfa Mehmet Akif Inan Education and Research Hospital
HPV - Anogenital Human Papilloma Virus Infection, HSIL, High Grade Squamous Intraepithelial Lesions
E6/E7 mRNA Performance to Detect HSIL and Cost-effectiveness Analysis of This Screening Strategy in HIV + MSM
This study evaluates the positive and negative predictive value of E6/E7 mRNA expression for anal HSIL and its capacity to predict incident HSIL in HIV + MSM. We also analyse the cost-effectiveness of this new screening strategy.
- Conditions
- HPV - Anogenital Human Papilloma Virus Infection, HSIL, High Grade Squamous Intraepithelial Lesions, Anal Cancer, Hiv
- Trial name
- ELAVI-67 (NCT03357991)
- Where
- Spain
- Volunteers
- 355 people
- Sponsor
- Hospital Universitari de Bellvitge
Papillomavirus Infections
A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).
This study will evaluate the safety, tolerability, and immunogenicity of V503 in Japanese girls between the ages of 9 and 15 and will determine whether V503 induces an acceptable immune response to all human papillomavirus (HPV)…
- Trial name
- NCT01254643
- Testing
- V503
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection
Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV
The proposed study is a substudy of ATN 106 and a cross sectional study intended to be conducted at each of the AMTUs newly participating in ATN III.
- Trial name
- NCT01492842
- Where
- 5 sites in United States
- Volunteers
- 272 people
- Sponsor
- University of North Carolina, Chapel Hill
Human Papilloma Virus (HPV), Hearing Disability
Knowledge and Beliefs of Hearing Impaired Individuals Regarding Human Papillomavirus (HPV)
Health education is one approach to influencing individuals, groups, or communities to achieve better health. The literature indicates that increasing awareness of HPV, along with participation in early screening and vaccination…
- Trial name
- HPV (NCT07207655)
- Testing
- HPV Card Game
- Volunteers
- 40 people
- Sponsor
- Çankırı Karatekin University
Vulvar Intraepithelial Neoplasia, Condylomata Acuminata
Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study
The study is a single arm, retrospective, single-center, post market registry. The purpose of this Registry is to collect data to demonstrate the safety and performance of CUSA® for the treatment of Vulvar Intraepithelial…
- Trial name
- NCT06297187
- Testing
- CUSA (Cavitronic Ultrasonic Surgical Aspirator)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Integra LifeSciences Corporation
Uterine Cervical Neoplasms, HIV I Infection
Cervical Pre-cancer Treatment Failure Among Women Living With HIV in Zimbabwe
The goal of this observational study is to improve cervical pre-cancer treatment outcomes among women living with HIV (WLWH), particularly in low and middle income countries (LMICs), by generating the evidence needed for…
- Conditions
- Uterine Cervical Neoplasms, HIV I Infection, HPV Infection
- Trial name
- NCT07202936
- Where
- Zimbabwe
- Volunteers
- 168 people
- Sponsor
- University of Bern
Cervix Cancer, Human Papilloma Virus
Relational Agents in Cervical Cancer Education (RACE)
The goal of this clinical trial is to assess the feasibility of using interactive teaching to educate cervical cancer patients about Human papillomavirus (HPV) and HPV vaccinations.
- Conditions
- Cervix Cancer, Human Papilloma Virus, Vaginal Cancer, Vulvar Cancer
- Trial name
- RACE (NCT06537687)
- Testing
- Control, Intervention
- Where
- 2 sites in United States
- Volunteers
- 91 people
- Sponsor
- Radhika Gogoi
Infections, Papillomavirus
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
The purpose of this post-marketing study is to evaluate the incidence of autoimmune diseases (AIDs) following females who have received at the least the first dose of Cervarix® as part of their routine health care.
- Trial name
- NCT01153906
- Testing
- Data collection
- Where
- United States
- Volunteers
- 1,516 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Male Infertility
Human Papilloma Virus In Male Infertility
Infertility is a major health problem worldwide and is estimated to affect 8-12% of couples in the reproductive age group. Infertility affects both men and women. Male causes for infertility are found in 50% of these couples.
- Trial name
- NCT07121530
- Testing
- HPV infection in infertile males
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- South Valley University
Infection With Human Papillomavirus
Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)
Six identical female twins aged 9-13 years will participate. One sib of each twin pair will be given Cervarix according to the 0, 1, 6 month vaccination scheme, while the other sib will be given Gardasil according to the 0, 2, 6…
- Trial name
- HPVXneutra001 (NCT01914367)
- Testing
- cervarix, Gardasil
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.